Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type 2 diabetes and obesity, have evolved into multi-organ potential therapeutics due to their pleiotropic effects beyond glycemic control
The company will continue to cover these drugs for diabetes treatment and may offer large employers the option to keep weight-loss coverage
Oral semaglutides availability and indication for weight management may differ by market and formulation
Diabetes (2002) 51:94350
Kieffer TJ, McIntosh CHS, Pederson TA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
:max_bytes(150000):strip_icc()/Health-GettyImages-2153927815-0bf99cd73e2c46908d7fc0973739f6d0.jpg)
